サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1243852

悪性中皮腫の世界市場

Malignant Mesothelioma
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
悪性中皮腫の世界市場
出版日: 2023年03月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

悪性中皮腫の世界市場は、2030年に8億7,470万米ドルに達する

COVID-19後の変化したビジネス環境において、2022年に5億4,070万米ドルと予測される悪性中皮腫の世界市場は、2030年までに8億7,470万米ドルに達すると予測され、2022年から2030年にかけてCAGR6.2％で成長するとされています。本レポートで分析したセグメントの1つであるPremetrexed &Combinationは、CAGR 6.8%を記録し、分析期間終了時には4億6,860万米ドルに到達すると予測されています。パンデミック後の回復を考慮し、シスプラチン＆コンビネーション分野の成長率は、今後8年間のCAGRを6%に修正しました。

米国市場は1億6,270万米ドル、中国はCAGR5.7%で成長すると予測される

米国の悪性中皮腫市場は、2022年に1億6,270万米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが5.7%で、2030年には1億5,050万米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ6％と4.8％の成長が予測されています。欧州では、ドイツがCAGR5.1%で成長すると予測されています。

調査対象企業の例

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Concordia International Corporation
  • Corden Pharma International GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • MolMed S.p.A.
  • Mylan NV
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Novartis International AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Polaris Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP13152

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Malignant Mesothelioma Market to Reach $874.7 Million by 2030

In the changed post COVID-19 business landscape, the global market for Malignant Mesothelioma estimated at US$540.7 Million in the year 2022, is projected to reach a revised size of US$874.7 Million by 2030, growing at aCAGR of 6.2% over the period 2022-2030. Premetrexed & Combination, one of the segments analyzed in the report, is projected to record 6.8% CAGR and reach US$468.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cisplatin & Combination segment is readjusted to a revised 6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $162.7 Million, While China is Forecast to Grow at 5.7% CAGR

The Malignant Mesothelioma market in the U.S. is estimated at US$162.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$150.5 Million by the year 2030 trailing a CAGR of 5.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6% and 4.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Select Competitors (Total 43 Featured) -

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Concordia International Corporation
  • Corden Pharma International GmbH
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • MolMed S.p.A.
  • Mylan NV
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Novartis International AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Polaris Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Malignant Mesothelioma - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Malignant Mesothelioma Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Premetrexed & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Premetrexed & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 7: World 16-Year Perspective for Premetrexed & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cisplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cisplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 10: World 16-Year Perspective for Cisplatin & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Carboplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Carboplatin & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for Carboplatin & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gemcitabine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gemcitabine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Gemcitabine & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Vinorelbine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Vinorelbine & Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Vinorelbine & Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • JAPAN
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • CHINA
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: China 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • EUROPE
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • FRANCE
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: France 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • GERMANY
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Malignant Mesothelioma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Rest of World Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: Rest of World 16-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed & Combination, Cisplatin & Combination, Carboplatin & Combination, Gemcitabine & Combination, Vinorelbine & Combination and Other Drug Classes for the Years 2014, 2023 & 2030

IV. COMPETITION